Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGPS1 | O95749 | 2/20 | 0.43 |
| ▸ | SLC9A1 | P19634 | 3/20 | 0.41 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.37 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.34 |
| ▸ | MGLL | Q99685 | 2/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16815645 | 0.93 | GGPS1 (0.40) | GGPS1SLC9A1HCAR3PTGS2 | |
| SCHEMBL24754052 | 0.86 | SLC9A1 (0.42) | GGPS1SLC9A1PTGS1PTGS2MGLL | |
| SCHEMBL10079215 | 0.86 | SLC9A1 (0.42) | GGPS1SLC9A1PTGS1PTGS2MGLL | |
| SCHEMBL5656543 | 0.85 | GGPS1 (0.36) | GGPS1SLC9A1HCAR3PTGS2 | |
| SCHEMBL3540514 | 0.84 | GGPS1 (0.53) | GGPS1SLC9A1PTGS1PTGS2MGLL | |
| SCHEMBL24975735 | 0.84 | GGPS1 (0.53) | GGPS1SLC9A1PTGS1PTGS2MGLL | |
| SCHEMBL17167330 | 0.84 | GGPS1 (0.50) | GGPS1SLC9A1PTGS1PTGS2MGLL | |
| SCHEMBL21318209 | 0.84 | GGPS1 (0.53) | GGPS1SLC9A1PTGS1PTGS2MGLL | |
| SCHEMBL9926297 | 0.84 | GGPS1 (0.47) | GGPS1SLC9A1PTGS1PTGS2MGLL | |
| SCHEMBL23619204 | 0.84 | GGPS1 (0.53) | GGPS1SLC9A1PTGS1PTGS2MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2451286-B1 | 4- AND 5 SUBSTITUTED 1,2,3- TRIAZOLE MOIETIES WITH AT LEAST ONE REMOTE POLYMERIZABLE MOIETY AND POLYMERS THEREOF | ISP INVESTMENTS INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-8993698-B2 | 4- and 5 substituted 1,2,3-triazole moieties with at least one remote polymerizable moiety and polymers thereof | ISP INVESTMENTS INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20120142846-A1 | 4- AND 5 SUBSTITUTED 1,2,3-TRIAZOLE MOIETIES WITH AT LEAST ONE REMOTE POLYMERIZABLE MOIETY AND POLYMERS THEREOF | AVOCA LLC | 2012-06-07 | — | — | US | disclosed |
| EP-2451286-A1 | 4- AND 5 SUBSTITUTED 1,2,3- TRIAZOLE MOIETIES WITH AT LEAST ONE REMOTE POLYMERIZABLE MOIETY AND POLYMERS THEREOF | Isp Investments Inc. (US) | 2012-05-16 | — | — | EP | disclosed |
| WO-2011005806-A1 | 4- AND 5 SUBSTITUTED 1,2,3- TRIAZOLE MOIETIES WITH AT LEAST ONE REMOTE POLYMERIZABLE MOIETY AND POLYMERS THEREOF | ISP INVESTMENTS INC. (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142846-A1 | 4- AND 5 SUBSTITUTED 1,2,3-TRIAZOLE MOIETIES WITH AT LEAST ONE REMOTE POLYMERIZABLE MOIETY AND POLYMERS THEREOF | H1-4, NPY4R, RXFP4 | GGPS1 3722/4885SLC9A1 4493/4885SMPD1 4617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.